microRNA-1246 (miR-1246)

microRNA-1246 (miR-1246) is a small non-coding RNA molecule that serves as a critical post-transcriptional regulator of gene expression. It is widely recognized as a potent oncomiR, frequently overexpressed in a variety of human cancers, including breast, colorectal, lung, and pancreatic cancers, where it promotes cell proliferation, invasion, and resistance to chemotherapy. miR-1246 exerts its oncogenic effects by targeting and silencing tumor suppressor genes such as CCNG2, AXIN2, and GSK3B, which in turn activates pro-survival pathways like Wnt/beta-catenin and PI3K/AKT. Notably, miR-1246 is highly enriched in tumor-derived exosomes and is detectable in the blood, making it a valuable non-invasive biomarker for cancer diagnosis and prognosis. Therapeutic strategies currently under investigation involve the use of antagomirs or antisense oligonucleotides to neutralize miR-1246 activity, thereby restoring tumor suppressor function and sensitizing cancer cells to standard treatments like docetaxel.

Other names

hsa-miR-1246MIR1246microRNA 1246

Inhibition of miR-1246 using antisense oligonucleotides or antagomirs prevents the mature miRNA from binding to the 3' untranslated regions (UTRs) of its target mRNAs, such as CCNG2, AXIN2, and GSK3B. This restoration of tumor suppressor expression leads to the inhibition of oncogenic signaling pathways, including Wnt/beta-catenin and PI3K/AKT, thereby reducing tumor growth and metastasis.